Meyers-Riggs, B. Phytocannabinoids. countyourculture, countyourculture: rational exploration of the underground, 26 Oct 2010. #CBD
Potter, DJ; Hammond, K; Tuffnell, S; Walker, C; Forti, MD. Potency of Δ9-tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test. Anal., 1 Apr 2018, 10 (4), 628–635. 470 kB. https://doi.org/10.1002/dta.2368
Shulgin, AT. Chemistry of psychotomimetics. In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1
Shulgin, AT. Hallucinogens. In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., John Wiley & Sons, Inc., 1 Jan 1981; pp 1109–1137. 4.7 MB. #56
Shulgin, AT. Psychotomimetic agents. In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #XCI
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #2
Russo, EB; Marcu, J. Cannabis pharmacology: The usual suspects and a few promising leads. In Adv. Pharmacol.; , Elsevier, 1 Jan 2017; pp 67–134. 1.6 MB. https://doi.org/10.1016/bs.apha.2017.03.004 #Cannabidiol
Weissman, A; Milne, GM; Melvin, LS. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J. Pharmacol. Exp. Ther., 1 Nov 1982, 223 (2), 516–523. 2.8 MB. #Cannabidiol
Banister, SD; Kumar, KK; Kumar, V; Kobilka, BK; Malhotra, SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain. Med. Chem. Commun., 22 May 2019, 10 (5), 647–659. 810 kB. https://doi.org/10.1039/C8MD00595H #4
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol. ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #2a
Al-Zoubi; Morales; Reggio. Structural Insights into CB1 Receptor Biased Signaling. Int. J. Mol. Sci., 13 Apr 2019, 20 (8), 1837. 3.4 MB. https://doi.org/10.3390/ijms20081837 #CBD
Churchill, KT. Synthetic tetrahydrocannabinol. J. Forensic Sci., 1 Jul 1983, 28 (3), 762–772. 352 kB. https://doi.org/10.1520/JFS11571J #CBD GC,MS,NMR
Worob, A; Wenthur, C. DARK classics in chemical neuroscience: Synthetic cannabinoids (Spice/K2). ACS Chem. Neurosci., 2 Dec 2020, 11 (23), 3881–3892. 1.5 MB. https://doi.org/10.1021/acschemneuro.9b00586 #2
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB. #5.2
Shulgin, AT. Recent developments in cannabis chemistry. J. Psychoactive Drugs, 1 Oct 1968, 2 (1), 15–29. 1.3 MB. https://doi.org/10.1080/02791072.1968.10524397 #III
Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1 Jan 1970; pp 21–41. 8.6 MB. #Cannabidiol
Bailey, K; Gagné, DR. Distinction of synthetic cannabidiol, cannabichromene, and cannabivarin by GLC using on-column methylation. J. Pharm. Sci., 1 Oct 1975, 64 (10), 1719–1720. 169 kB. https://doi.org/10.1002/jps.2600641033 #I GC,MS
Razdan, RK. The Total Synthesis of Cannabinoids. In Total Synthesis of Natural Products; ApSimon, J, Ed., John Wiley & Sons, 1 Jan 1981; Vol. 4, pp 185–262. 4.0 MB. https://doi.org/10.1002/9780470129678.ch2 #12